Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.54 |
| ▸ | ABL1 | P00519 | 3/20 | 0.51 |
| ▸ | BCR | P11274 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.50 |
| ▸ | WEE2 | P0C1S8 | 2/20 | 0.50 |
| ▸ | WEE1 | P30291 | 2/20 | 0.50 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.50 |
| ▸ | STK25 | O00506 | 1/20 | 0.49 |
| ▸ | CIT | O14578 | 1/20 | 0.49 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.49 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | CASK | O14936 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.49 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487395 | 0.96 | SRC (0.53) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL2977174 | 0.95 | SRC (0.54) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL22589482 | 0.91 | SRC (0.59) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL14418088 | 0.91 | SRC (0.57) | SRCABL1BCRWEE2WEE1 | |
| SCHEMBL29365909 | 0.91 | SRC (0.59) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5467921 | 0.91 | SRC (0.53) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL7069504 | 0.90 | SRC (0.53) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL4741681 | 0.90 | SRC (0.66) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL1893090 | 0.89 | SRC (0.62) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL29590073 | 0.89 | SRC (0.62) | SRCABL1BCREGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101792416-B | Process for preparing bosutinib | UNIV NANJING MEDICAL | 2011-10-05 | — | — | CN | claimed |
| CN-101792416-A | Process for preparing bosutinib | UNIV NANJING MEDICAL | 2010-08-04 | — | — | CN | claimed |
| WO-2023141635-A2 | HER3 LIGANDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2017134679-A1 | NOVEL CRYSTALLINE POLYMORPHS OF 4-[(2.4-DICHIORO-5-METHOXVPHENVL)ANIINOL- 6-METHOXV-7-13-(4-METHYL-L-PIPERAZINVL)PROPOXVL-3-QUINOLINECARBONITRILE AND PROCESS FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-08-10 | — | — | WO | disclosed |
| WO-2015198249-A1 | PROCESS FOR PREPARATION OF BOSUTINIB | SHILPA MEDICARE LIMITED (IN) | 2015-12-30 | — | — | WO | disclosed |
| CN-101792416-B | Process for preparing bosutinib | UNIV NANJING MEDICAL | 2011-10-05 | — | — | CN | disclosed |
| CN-101792416-A | Process for preparing bosutinib | UNIV NANJING MEDICAL | 2010-08-04 | — | — | CN | disclosed |
| US-20090264427-A1 | 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264427-A1 | 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264427-A1 | 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-6384051-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2002-05-07 | — | — | US | disclosed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| CN-1259125-A | Substituted 3-cyanoquinolines | AMERICAN CYANAMID CO (US) | 2000-07-05 | — | — | CN | disclosed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | disclosed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264427-A1 | 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors | IGF1R, IGFBP1, IGFBP2 | SRC 993/4885ABL1 158/4885BCR 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.